-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Fecal bacteriota transplantation (FMT) is recommended to treat relapsed Tract infection (rCDI).
we conducted a single-center randomized trial to compare the efficacy of FMT with non-dassomycin and vancomycin.
we studied adults with rCDI who were continuously observed at gastroenterology clinics in Denmark from 5 April 2016 to 10 June 2018.
patients were randomly assigned to a group that received vancomycin for 4-10 days (125 mg, 4 times a day; FMTv; n s 24), non-dassomycin for 10 days (200 mg, twice a day; n s 24) or vancomycin for 10 days (125 mg, 4 times a day; n s 16), through a colonoscopy.
patients with rCDI after this course and patients who could not be randomly assigned to each group provided rescue FMTv.
outcomes were negative results in a polymerase chain reaction trial that combined clinical solutions with difficult Thyrobacteria (CD) toxins after 8 weeks of assigned treatment.
outcomes include the clinical approach of week 8.
results showed that all 64 patients received the assigned treatment.
gave FMTv (71%), 8 fidamycin (33%) and 3 vancomycin (19%; FMTv VS fidamycin P . . . 009;FMTv VS Vancomycin's P s.001; Fidamycin VS vancomycin's P s.31) observed a combination of clinically addressed and NEGATIVE results of CD testing.
Clinical solution was observed in 22 patients given FMTv (92%), clinical solutions were observed in 10 patients given Fidasomis (42%) and clinical solutions were observed in 3 patients given vancomycin (19%;P s.0002; P slt; .0001; P s.13).
there was no significant difference in outcomes between patients who received FMTv as the initial treatment and those who received FMTv.
one serious adverse event may be related to FMTv.
In summary, the results showed that in a randomized trial of rCDI patients, we found that FMTv combined therapy was superior to nondamycin or vancomycin based on clinical and microbiological solutions or endpoints of individual clinical solutions.
.
